<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC 2024 19_11-12_479</article-id>
<article-id pub-id-type="doi">10.15836/ccar2024.479</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
<subj-group subj-group-type="subheading"><subject>Interventional cardiology</subject></subj-group>
</article-categories>
<title-group>
<article-title>Optimal vascular closure after transcatheter aortic valve implantation: managing the most frequent complication</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3768-9134</contrib-id><name><surname>Had&#x017E;ibegovi&#x0107;</surname><given-names>Irzal</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2740-4067</contrib-id><name><surname>Uni&#x0107;</surname><given-names>Daniel</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8652-4523</contrib-id><name><surname>&#x0160;ipi&#x0107;</surname><given-names>Tomislav</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9187-7681</contrib-id><name><surname>Pavlovi&#x0107;</surname><given-names>Nikola</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3962-2774</contrib-id><name><surname>Pavlov</surname><given-names>Marin</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6983-1409</contrib-id><name><surname>Vitlov</surname><given-names>Petra</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4304-1852</contrib-id><name><surname>Gjorgjievska</surname><given-names>Savica</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7735-6721</contrib-id><name><surname>Rude&#x017E;</surname><given-names>Igor</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6444-2674</contrib-id><name><surname>Manola</surname><given-names>&#x0160;ime</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2637-9691</contrib-id><name><surname>Jurin</surname><given-names>Ivana</given-names></name></contrib>
<aff id="aff1"><institution>Dubrava University Hospital</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Irzal Had&#x017E;ibegovi&#x0107;, Klini&#x010D;ka bolnica Dubrava, Avenija Gojka &#x0160;u&#x0161;ka 6, HR-10000 Zagreb, Croatia. / Phone: +385-91-5333-091 / E-mail: <email xlink:href="irzalh@gmail.com">irzalh@gmail.com</email></corresp></author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>11</month><year>2024</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>11</month><year>2024</year></pub-date>
<volume>19</volume>
<issue>11-12</issue>
<fpage>479</fpage>
<lpage>479</lpage>
<history>
<date date-type="received"><day>13</day><month>10</month><year>2024</year></date>
<date><day>31</day><month>10</month><year>2024</year></date>
</history>
<permissions>
<copyright-statement>Croatian Cardiac Society</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>transcatheter aortic valve implantation</kwd><kwd>hemostasis</kwd><kwd>perclose device</kwd><kwd>vascular seal</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction</bold>: Percutaneous hemostasis after transcatheter aortic valve implantation (TAVI) involves perclose devices, vascular seal devices, hemostatic bands, or combinations of any of them. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) We present our experiences with full percutaneous hemostasis after transfemoral TAVI achieved by two different strategies involving perclose devices.</p>
<p><bold>Patients and Methods</bold>: Patients who underwent full percutaneous transfemoral TAVI between October 2019 and September 2024 were included in the analysis. In total, 465 patients were divided in two groups: 176 patients who systematically received two perclose devices as a primary closure strategy from October 2019 to November 2022 were assigned to group 2PC, whereas the group 1PC+1VS consisted of 289 patients who systematically received one perclose device with one 8 French vascular seal from December 2022 to September 2024. Primary endpoint was a composite of 30-day major and minor vascular complications defined by VARC-3 consortium.</p>
<p><bold>Results:</bold> There were no significant differences in demographic and clinical characteristics between the groups. Primary endpoint occurred in 12 (6.8%) patients in the group2PC and in 22 (7.6%) patients in the group 1PC+1VS (RR 1.12 95% CI 0.57-2.20 for VARC-3 major or minor vascular complication). Proportion of major vascular complications was higher in the 2PC group (1.7% vs 1%), but that difference was not significant. Logistic regression showed independent association of age (RR 1.08 95% CI 1.01-1.16) and peripheral artery disease (RR 2.66 95% CI 1.26-5.61) with the primary endpoint. There were no significant differences in primary endpoint regarding closure technique in the whole cohort, and also among different TAVI devices or sizes within both groups.</p>
<p><bold>Conclusions</bold>: Hybrid vascular closure with one perclose and one 8 French vascular seal showed similar safety with relatively lower proportion of major vascular complications compared to a standard technique using two perclose devices, irrespective of TAVI platform or size. Age and peripheral artery disease were the only variables independently associated with vascular complications.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Had&#x017E;ibegovi&#x0107;</surname><given-names>I</given-names></name><name><surname>Uni&#x0107;</surname><given-names>D</given-names></name><name><surname>Jurin</surname><given-names>I</given-names></name><name><surname>Bradi&#x0107;</surname><given-names>N</given-names></name><name><surname>Star&#x010D;evi&#x0107;</surname><given-names>B</given-names></name><name><surname>Rude&#x017E;</surname><given-names>I</given-names></name></person-group>. <article-title>Percutaneous transfemoral approach and additional vascular access selection influence hospital stayandsurvival after transcatheter aortic valve implantation.</article-title> <source>Cardiol Croat</source>. <year>2021</year>;<volume>16</volume>(<issue>1-2</issue>):<fpage>36</fpage>. <pub-id pub-id-type="doi">10.15836/ccar2021.36</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
